• Home
  • Search Results
  • Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.

Clinical cancer research : an official journal of the American Association for Cancer Research (2014-09-17)
Miguel F Sanmamed, Omar Carranza-Rua, Carlos Alfaro, Carmen Oñate, Salvador Martín-Algarra, Guiomar Perez, Sara F Landazuri, Alvaro Gonzalez, Stefanie Gross, Inmaculada Rodriguez, Cecilia Muñoz-Calleja, María Rodríguez-Ruiz, Bruno Sangro, José M López-Picazo, Manglio Rizzo, Guillermo Mazzolini, Juan I Pascual, Maria Pilar Andueza, Jose Luis Perez-Gracia, Ignacio Melero
ABSTRACT

Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. We correlated IL8 serum levels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Human IL-6 ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Mouse IL-6 ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Rat IL-6 ELISA Kit, for serum, plasma and cell culture supernatants
Sigma-Aldrich
Human IL-6 ELISA Kit, for cell and tissue lysates
Sigma-Aldrich
Mouse IL-6 ELISA Kit, for cell and tissue lysates
Sigma-Aldrich
Rat Interleukin-6 ELISA Kit, for for cell lysate and tissue lysate
Sigma-Aldrich
Human IL-6 sR ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Mouse IL-6 R ELISA Kit, for serum, plasma and cell culture supernatant